Drugs / E7090
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | biliary tract cancer | 2026-02-11 | “该研究是tasurgratinib此前在日本获得批准的关键依据，也是其当前在中国进行新药上市申请的主要依据之一。” sciclone.com ↗ |
| Filed | Japan (PMDA) | — | biliary tract cancer | 2023-12-18 | “it has submitted a marketing authorization application in Japan” eisai.com ↗ |
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04565574 | Oct 2020 → Mar 2021 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04572295 | Oct 2020 → Jun 2026 | breast neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04493255 | Sep → Oct 2020 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04271488 | Feb 2020 → Aug 2027 expected | — | Eisai Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT02275910 | Oct 2014 → Sep 2021 | neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04962867 | Jun 2021 → Mar 2028 expected | cancer | National Cancer Center, Japan | Recruiting | No outcome recorded |
| Phase 2 | NCT04238715 | Jan 2020 → Nov 2025 | cholangiocarcinoma | Eisai Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
All press releases naming this drug 8 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7090 | “Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared...” NCT04271488 ↗ |
| Known as | tasurgratinib | “E7090 (tasurgratinib) is an orally available selective tyrosine kinase inhibitor of FGFR1-3.” PMID 35945547 ↗ Aug 2022 |
| Action | Inhibit | “selective tyrosine kinase inhibitor of FGFR1-3” PMID 35945547 ↗ Aug 20222“Fibroblast growth factor receptor 2 inhibitor” CHEMBL3686884 ↗ “Fibroblast growth factor receptor 3 inhibitor” CHEMBL3686884 ↗ |
| Modality | Small molecule | — CHEMBL3686884 ↗ |
| Route | Oral | “Oral, starting dose 1 mg once a day” NCT02275910 ↗ |
| Target | FGFR1 | “E7090 (tasurgratinib) is an orally available selective tyrosine kinase inhibitor of FGFR1-3.” PMID 35945547 ↗ Aug 2022 |
| Target | FGFR2 | “Fibroblast growth factor receptor 2 inhibitor” CHEMBL3686884 ↗ |
| Target | FGFR3 | “Fibroblast growth factor receptor 3 inhibitor” CHEMBL3686884 ↗ |